0
0
Philadelphia, PA – In a milestone for genetic medicine, a baby born with a rare and deadly genetic disorder is now thriving after receiving a groundbreaking, custom-made gene editing therapy. The case, detailed in a study published Thursday in the New England Journal of Medicine, marks a significant step toward personalized treatments for rare diseases that have long been untreatable.
A Life-Saving Breakthrough
KJ Muldoon, from Clifton Heights, Pennsylvania, was diagnosed shortly after birth with severe CPS1 deficiency-a condition so rare it affects only about one in a million babies. The disorder prevents the body from removing toxic ammonia from the blood, often leading to fatal outcomes. With limited options and a grim prognosis, KJ’s parents, Kyle and Nicole Muldoon, faced a difficult choice between an invasive liver transplant and an experimental therapy that had never been tried before.
After careful consideration, they opted for the new treatment, developed in just six months by a team at Children’s Hospital of Philadelphia (CHOP) and Penn Medicine. Using a refined form of CRISPR gene editing called “base editing,” doctors precisely corrected the single-letter mutation in KJ’s DNA responsible for his condition. Unlike traditional CRISPR, which cuts DNA strands, base editing swaps out the faulty genetic “letter” with the correct one, reducing the risk of unintended changes.
Rapid Results and Renewed Hope
In February, KJ received his first infusion of the gene editing therapy, delivered via lipid nanoparticles targeting his liver cells. Additional doses followed in March and April. Since then, he has shown remarkable improvement-eating more normally, recovering well from illnesses, and reducing his medication intake.
“Every day, he’s showing us signs that he’s growing and thriving,” said Dr. Rebecca Ahrens-Nicklas, a gene therapy expert at CHOP and one of the study’s authors. KJ’s parents celebrate each new milestone, from waving to rolling over, as a testament to the treatment’s impact.
Implications for the Future
Experts say this case could pave the way for similar therapies for millions of people worldwide living with rare genetic diseases. Dr. Kiran Musunuru, a University of Pennsylvania gene editing expert and co-author of the study, called it “the first step towards the use of gene editing therapies to treat a wide variety of rare genetic disorders for which there are currently no definitive medical treatments.”
While gene therapies have traditionally focused on more common disorders due to high development costs, this study demonstrates that custom treatments for rare diseases may be more feasible than previously thought. Musunuru noted that the cost of developing KJ’s therapy was comparable to that of a liver transplant, and expects prices to fall as the technology advances.
Researchers caution, however, that it is still early days. KJ will need to be monitored for years to fully understand the long-term effects of the therapy. Nevertheless, the rapid development and success of this personalized treatment offer hope that similar approaches could soon benefit others with rare genetic conditions.
Disclaimer:
This article is based on information from a study published in the New England Journal of Medicine and reporting by the Associated Press. The described therapy is experimental and not yet widely available. Long-term outcomes are still being evaluated. Anyone considering gene editing treatments should consult with qualified medical professionals.
Citations:
